开能健康科技集团股份有限公司董事会 关于独立董事独立性情况的专项意见 根据《上市公司独立董事管理办法》《深圳证券交易所创业板股票上市规则》 《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》 等要求，开能健康科技集团股份有限公司（以下简称"公司"）董事会，就公司 2024 年度独立董事朱震宇、侯郁波及王高①的独立性情况进行评估并出具如下专项意 见： 开能健康科技集团股份有限公司 董 事 会 二○二五年四月二十五日 ① 2024 年 2 月 26 日，公司披露《关于独立董事辞职的公告》，王高于 2024 年 2 月 26 日连 续担任本公司独立董事期满六年离任。 经核查报告期内公司独立董事的任职经历以及签署的相关自查文件，上述人 员未在公司担任除独立董事以外的任何职务，也未在公司主要股东公司担任任何 职务，与公司以及主要股东之间不存在利害关系或其他可能妨碍其进行独立客观 判断的关系。因此，公司独立董事符合《上市公司独立董事管理办法》《深圳证 券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号 ——创业板上市公司规范运作》中对独立董事独立性的相关要求。 ...

开能健康科技集团股份有限公司 开能健康科技集团股份有限公司 2024年度独立董事述职报告 （王高） 本人作为开能健康科技集团股份有限公司（以下简称"公司"）独立董事，严格 按照《公司法》《证券法》《上市公司独立董事管理办法》《深圳证券交易所创业板 股票上市规则》《深圳证券交易所上市公司自律监管指引第2号—创业板上市公司规 范运作》及《公司章程》《独立董事工作制度》等相关法律法规和规章制度的规定， 认真履行职责，充分发挥独立董事的独立作用，维护公司整体利益，维护全体股东尤 其是中小股东的合法权益。 因担任公司独立董事已满六年，根据监管规定，自2024年2月26日起不再担任公 司独立董事及董事会专门委员会相关职务，现就本人2024年度任职期间履行独立董事 职责情况汇报如下： 一、年度履职概况 （一）出席董事会和股东大会情况 2024年度，公司共召开10次董事会会议，4次股东大会，本人出席情况如下： | 应出席董事 | 现场出席董 | 以通讯方式 出席董事会 | 委托出席董 | 缺席董事会 | 是否连续两 次未亲自参 | 出席股东大 | | --- | --- | --- | --- | --- | --- | - ...

开能健康科技集团股份有限公司 开能健康科技集团股份有限公司 2024年度独立董事述职报告 （朱震宇） 作为公司独立董事，本人具备法律法规所要求的专业性、独立性，任职符合《上 市公司独立董事管理办法》第六条规定的独立性要求，不存在影响独立性的情况。本 人履历如下： 朱震宇，1961年2月出生，中国国籍，无永久境外居留权，九三学社社员，高级 会计师，博士研究生学历，具有注册会计师，资产评估师，房地产估价师执行资格， 上海宏大东亚会计师事务所董事长，历任广船国际独立董事、中国船舶独立董事、申 华控股独立董事。现任中国菱镁行业协会副会长,上海市注册会计师协会理事,江苏宏 海新型材料有限公司董事长,上海宏大拍卖有限公司董事长。上海大学硕士生导师,上 海财经大学硕士生导师。现任天和磁材（603072）独立董事、辽宁能源（600758）独 立董事。2023年5月19日至今任公司独立董事。 二、年度履职概况 （一）出席董事会和股东大会情况 2024年度，公司共召开10次董事会会议，4次股东大会，本人出席情况如下： 开能健康科技集团股份有限公司 | 应出席董 | 现场出席 董事会次 | 以通讯方式出 | 委托出席 董事会次 | ...

开能健康科技集团股份有限公司 开能健康科技集团股份有限公司 2024年度独立董事述职报告 （侯郁波） 本人作为开能健康科技集团股份有限公司（以下简称"公司"）第六届董事会独 立董事，严格按照《公司法》《证券法》《上市公司独立董事管理办法》《深圳证券 交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第2号—创业 板上市公司规范运作》及《公司章程》《独立董事工作制度》等相关法律法规和规章 制度的规定，认真履行职责，充分发挥独立董事的独立作用，维护公司整体利益，维 护全体股东尤其是中小股东的合法权益。 现将2024年度本人担任公司独立董事期间的履职情况报告如下： 一、基本情况 作为公司独立董事，本人具备法律法规所要求的专业性、独立性，任职符合《上 市公司独立董事管理办法》第六条规定的独立性要求，不存在影响独立性的情况。本 人履历如下： 侯郁波，1969年11月生，中国国籍，无永久境外居留权，中共党员，北京大学硕 士学位。曾先后任上海延中实业股份有限公司（沪市老八股600601）董事长秘书、董 事会授权代表；方正科技集团股份有限公司（600601）行政管理部副主任、战略发展 部副主任，党委书记、董事、副 ...

Financial Performance - The company's operating revenue for 2024 was CNY 1,688,500,855.60, representing a 1.01% increase compared to CNY 1,671,699,376.58 in 2023[18]. - The net profit attributable to shareholders for 2024 decreased by 36.90% to CNY 83,575,721.82 from CNY 132,446,680.84 in 2023[18]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 76,774,507.32, down 26.71% from CNY 104,756,280.97 in the previous year[18]. - The net cash flow from operating activities for 2024 was CNY 289,639,323.72, a decrease of 22.73% compared to CNY 374,830,410.27 in 2023[18]. - Basic earnings per share for 2024 were CNY 0.1476, down 37.40% from CNY 0.2358 in 2023[18]. - Total assets at the end of 2024 were CNY 2,956,338,872.28, a decrease of 1.40% from CNY 2,998,215,755.16 at the end of 2023[18]. - The net assets attributable to shareholders decreased by 5.86% to CNY 1,222,722,113.98 from CNY 1,298,766,271.23 in 2023[18]. - The weighted average return on net assets for 2024 was 6.63%, down from 11.42% in 2023, reflecting a decline of 4.79%[18]. Market and Industry Insights - The water appliance market is projected to reach ¥34.6 billion in retail sales for 2024, with a year-on-year growth of 16.3%[32]. - The penetration rate of household water treatment devices in China is approximately 23%, significantly lower than over 80% in developed countries, indicating substantial growth potential[31]. - The market potential for water treatment equipment in China is expected to exceed 80 billion yuan by 2030, driven by increasing health awareness and consumer demand[33]. - The shift in consumer demand indicates that water purifiers have transitioned from optional appliances to essential household items due to health needs[34]. Product Development and Innovation - The company has maintained a consistent focus on R&D for water treatment products, positioning itself as a leader in the industry with multiple key technologies[27]. - The company has accumulated 351 national authorized patents, including 56 invention patents, demonstrating its strong focus on innovation and R&D capabilities[81]. - The company completed 102 R&D projects in 2024, achieving a completion rate of 98% against the plan, and submitted 27 patent applications[83]. - The company aims to enhance its competitive edge by developing new products, including a low-end control valve and a central water treatment system, to capture market share[110]. Sales and Revenue Breakdown - Domestic market revenue reached CNY 597.77 million, accounting for 35.40% of total revenue, a decrease of 9.79% year-on-year[96]. - Overseas market revenue was CNY 1,090.73 million, representing 64.60% of total revenue, with terminal and service sales contributing CNY 673.77 million, or 39.90% of total revenue[96][97]. - Revenue from terminal business and services was CNY 1,010.66 million, accounting for 59.86% of total revenue, down 3.05% from the previous year[100]. - Revenue from intelligent manufacturing and core components was CNY 656.23 million, up 8.83% year-on-year, representing 38.86% of total revenue[100]. Operational Efficiency and Cost Management - The company has implemented a digital management system that has improved production efficiency and reduced costs[74]. - The company’s automated production lines have improved production efficiency, with the main valve body output increasing by 25.3% compared to the previous year[89]. - Direct material costs for water treatment equipment decreased by 2.37% to ¥751,623,994.28, accounting for 72.97% of total operating costs in 2024[105]. - Total sales expenses increased by 3.35% to ¥182,058,186.29, while management expenses rose by 10.85% to ¥234,685,375.11[108]. Risk Management and Strategic Planning - The company faces various risks including market risks, foreign operation risks, and financial risks from acquisitions, which are detailed in the report[3]. - The company has established a risk management strategy to address potential impacts from international trade policy changes, particularly regarding tariffs and trade barriers in North America[179]. - The company is addressing talent shortages by attracting high-potential talent and optimizing team structures to support business expansion[183]. Investor Relations and Corporate Governance - The company emphasizes investor relations management, ensuring timely and accurate information disclosure[198]. - The company has established multiple communication channels for investor inquiries and feedback[198]. - The performance evaluation standards for senior management are transparent and fair, with annual performance assessments conducted[200]. - The company adheres to governance regulations, ensuring effective operation of the shareholders' meeting, board of directors, and supervisory board[192].

Financial Performance - The company's operating revenue for Q1 2025 was CNY 405,475,102.35, representing a 6.31% increase compared to CNY 381,392,081.33 in the same period last year[5]. - Net profit attributable to shareholders was CNY 24,810,870.17, up 11.30% from CNY 22,291,406.17 year-on-year[5]. - Basic earnings per share increased by 12.28% to CNY 0.0439 from CNY 0.0391 year-on-year[5]. - Total operating revenue for the current period reached ¥405,475,102.35, an increase of 6.5% compared to ¥381,392,081.33 in the previous period[27]. - Net profit for the current period was ¥33,936,424.65, representing a 15.5% increase from ¥29,349,537.72 in the previous period[28]. - The net profit attributable to the parent company was ¥24,810,870.17, compared to ¥22,291,406.17, marking an increase of 11.3%[29]. - Basic earnings per share rose to ¥0.0439 from ¥0.0391, indicating a growth of 20.3%[29]. Cash Flow - The net cash flow from operating activities increased by 71.33%, reaching CNY 94,400,100.15 compared to CNY 55,098,547.27 in the previous year[5]. - Cash inflow from operating activities totaled ¥455,244,390.92, compared to ¥407,538,441.35 in the previous period, an increase of 11.7%[31]. - The net cash flow from operating activities was $94,400,100.15, an increase of 71.4% compared to $55,098,547.27 in the previous period[32]. - The total cash inflow from investment activities was $190,667,844.80, significantly up from $39,350.50 in the prior period[32]. - The net cash flow from investment activities was $65,195,218.31, recovering from a negative cash flow of -$16,469,475.66 in the previous period[32]. - The total cash inflow from financing activities was $279,906,783.72, slightly down from $289,242,477.08 year-over-year[32]. - The net cash flow from financing activities was $29,041,506.65, improving from a negative cash flow of -$36,861,551.98 in the previous period[32]. - The company reported a total cash outflow from operating activities of $360,844,290.77, compared to $352,439,894.08 in the prior period[32]. - The company’s cash flow from operating activities showed a strong performance despite an increase in cash outflows[32]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 3,030,683,344.92, a 2.51% increase from CNY 2,956,338,872.28 at the end of the previous year[5]. - The total assets of the company as of March 31, 2025, amounted to CNY 3,030,683,344.92, an increase from CNY 2,956,338,872.28 at the beginning of the period[22]. - Total liabilities increased to ¥1,685,121,305.49 from ¥1,645,242,044.47, reflecting a growth of 2.4%[26]. - The company's total liabilities as of March 31, 2025, were not explicitly stated but can be inferred from the balance sheet[22]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 22,018[14]. - The total number of restricted shares at the end of the period was 146,997,457, with no shares released during the current period[18]. - The company completed the transfer of 10,370,000 shares under the 2023 employee stock ownership plan, which has now been fully executed and terminated[20]. - As of March 31, 2025, the company had 2,496,851 convertible bonds remaining, with a total face value of CNY 24,968.51 million, accounting for 99.874% of the total issuance[21]. Inventory and Expenses - Inventory levels rose slightly to CNY 255,906,262.84 from CNY 253,991,509.81, indicating a marginal increase of about 0.8%[25]. - Short-term borrowings increased to CNY 585,476,378.67 from CNY 574,838,290.68, representing a rise of approximately 1.1%[25]. - The company experienced a 154.88% increase in financial expenses, totaling CNY 3,929,498.36, primarily due to a decrease in exchange gains[11]. - Research and development expenses decreased to ¥13,595,783.93 from ¥15,616,827.09, a decline of 12.9%[28]. - The company reported a decrease in financial expenses to ¥3,929,498.36 from ¥1,541,716.48, reflecting a significant increase in interest expenses[28]. Other Information - The company's cash and cash equivalents increased to CNY 789,047,614.73 from CNY 602,535,095.09, reflecting a growth of approximately 30.9%[22]. - The cash and cash equivalents net increase was CNY 188,331,745.49, a 5,059.52% increase from CNY 3,650,181.17 in the previous year[12]. - The first quarter report was not audited, indicating that the figures are preliminary and subject to change[33].

长江证券承销保荐有限公司 关于开能健康科技集团股份有限公司 2024 年度定期现场检查报告 根据中国证监会《证券发行上市保荐业务管理办法》和《深圳证券交易所上 市公司自律监管指引第 13 号——保荐业务》等有关法律法规的要求，长江证券 承销保荐有限公司作为开能健康科技集团股份有限公司（以下简称"开能健康" 或"公司"）向不特定对象发行可转换公司债券并在创业板上市的保荐人，于 2025 年 4 月 7 日至 4 月 8 日对开能健康 2024 年度有关情况进行了现场检查，报告如 下： | 保荐机构名称：长江证券承销保荐有限公司 被保荐公司简称：开能健康 | | | | | --- | --- | --- | --- | | 保荐代表人姓名：李光耀 联系电话：021-65779433 | | | | | 保荐代表人姓名：方雪亭 联系电话：021-65779433 | | | | | 现场检查人员姓名：李光耀、刘宇昂 | | | | | 年度 现场检查对应期间：2024 | | | | | 年 月 月 日 现场检查时间：2025 4 7 日-4 8 | | | | | 一、现场检查事项 | 现场检查意见 | | | ...

| 证券代码：300272 | 证券简称：开能健康 公告编号：2025-014 | | --- | --- | | 债券代码：123206 | 债券简称：开能转债 | 开能健康科技集团股份有限公司 关于公司使用自有资金进行委托理财的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 开能健康科技集团股份有限公司（以下简称"公司"或"开能健康"）于 2022 年 4 月 26 日召开了第五届董事会第十八次会议及第五届监事会第十四次会议， 审议通过《关于公司使用自有资金进行委托理财的议案》，公司董事会同意在保 证公司正常经营且保证资金安全的情况下，公司（含子公司）使用不超过 3 亿元 的闲置自有资金进行委托理财。该投资金额使用期限自公司董事会审议通过之日 起三年内有效，资金额度在决议有效期内可以滚动使用。公司董事会授权总经理 在额度范围内行使该项投资决策权及签署相关合同文件，财务部门负责具体办理 相关事宜。具体内容详见公司于 2022 年 4 月 28 日在符合条件的媒体披露的相关 公告。 近日，公司根据经营情况在上述使用期限及额度内，使用部分闲置自有资金 ...

| | | 开能健康科技集团股份有限公司 关于 2025 年第一季度可转债转股结果暨股份变动公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、"开能转债"（债券代码：123206）转股期限为 2024 年 1 月 26 日至 2029 年 7 月 19 日；最新的转股价格为人民币 5.40 元/股。 2、2025 年第一季度，共有 60 张"开能转债"完成转股，转成"开能健康"（股 票代码：300272）股票数量为 1,110 股。 3、截至 2025 年第一季度末，尚未转股的"开能转债"债券数量为 2,496,851 张，面值总额为 24,968.51 万元，占"开能转债"发行总量的比例为 99.874%。 根据《深圳证券交易所创业板股票上市规则》和《深圳证券交易所上市公司 自律监管指引第 15 号——可转换公司债券》的有关规定，开能健康科技集团股 份有限公司（以 下简称"公司"）现将本季度可转换公司债券（以下简称"可转 债"）转股及公司股份变化情况公告如下： 一、可转换公司债券基本情况 1、可转换公司债券发行情况 4、可转换债转股价格调 ...

| 证券代码：300272 | 证券简称：开能健康 | 公告编号：2025-012 | | --- | --- | --- | | 债券代码：123206 | 债券简称：开能转债 | | 购买情况： | 购买 | 发行主体 | 产品名称 | 产品类型 | 金额 | | 产品期限 | 预计年化收 | | --- | --- | --- | --- | --- | --- | --- | --- | | 主体 | | | | （万元） | | | 益率 | | 开能 | 兴业银行上 | 兴业银行企业 | 保本浮动 | | 2025 月 26 | 年 3 日至 | 1.3%-2.1% | | 健康 | 海分行 | 金融人民币结 构性存款产品 | 收益型 | 10,500 | 2025 | 年 6 | | | | | | | | 月 24 | 日 | | 赎回情况： | 购买 | 发行主体 | 产品名称 | 产品类 | 金额 | 收益金额 | 实际年化 | 公告 | | --- | --- | --- | --- | --- | --- | --- | --- | | 主体 | | | 型 | （万元） | （万元） ...